Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Eloxx Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2025
FY2025
Revenue
0
6.36
0
Research and development
0.73
16.4
20.5
26.3
14.6
22.9
23.7
8.6
3.58
3.06
General and administrative
1.41
2.7
26.5
24.2
14.8
20.4
10.7
8.69
5.25
3.38
Operating expenses
20.4
47.6
50.6
33.5
66
34.4
17.3
8.83
6.44
Operating income
-4.59
-20.4
-47.6
-50.6
-33.5
-66
-34.4
-17.3
-2.47
-6.44
Interest expense
0.04
Other non-operating income
-0.82
0.5
-0.32
-1.12
-0.71
-1.65
0.03
-0.05
0.03
Pre-tax income
-6.84
-21.2
-47.1
-50.9
-34.6
-66.7
-36.1
-17.1
-3.14
-6
Income tax
-1.04
0.12
0
0
0
0
0
0
0
Net income
-5.8
-21.2
-47.2
-50.9
-34.6
-66.7
-36.1
-17.1
-3.14
-6
EBITDA
-4.55
-20.4
-47.3
-50.5
-33.4
-65.9
-34.3
-17.2
-2.43
-6.44
EPS, basic
-10.84
-190.75
-58.23
-53.81
-34.54
-38.15
-16.65
-6.63
-0.84
-0.49
EPS, diluted
-10.84
-190.75
-58.23
-53.81
-34.54
-38.15
-16.65
-6.63
-0.84
-0.49
Shares, basic (weighted)
0.58
0.12
0.81
0.95
1
1.75
2.17
2.57
3.76
12.3
Shares, diluted (weighted)
0.58
0.12
0.81
0.95
1
1.75
2.17
2.57
3.76
12.3
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2025
FY2025
Cash and equivalents
13.4
24
48.6
22.5
24.7
42.3
19.2
1.13
0.11
4.79
Short-term investments
33.8
Other current assets
0.25
0.36
1.69
1.39
1.17
0.91
0.66
0.19
0.14
0.48
Total current assets
0.28
24.5
50.3
57.7
25.9
43.5
20.1
1.55
2.98
5.27
Property, plant and equipment
0.05
0.28
0.25
0.2
0.13
0.22
0.17
0.04
0
0
Lease right-of-use assets
0.92
0.42
1.44
0.83
0.13
0
0
Other non-current assets
0.13
0.11
0.03
Total assets
5.85
24.8
50.7
58.9
26.5
45.1
21.1
1.71
2.98
5.27
Accounts payable
0.19
1.53
0.75
1.87
0.48
1.38
3.02
5.7
5.35
2.71
Accrued liabilities
0.33
1.89
6.94
4.66
2.92
4.2
2.8
1.16
1.45
1.61
Short-term debt
4.34
5.24
0
3.98
2.22
6.52
1
Total current liabilities
2.77
3.42
7.81
11.8
9.84
9.96
23.1
22.7
27.3
17.2
Long-term debt
10.5
6.38
12
8.56
1.61
0
0
Lease liabilities
0.43
0.03
0.8
0.14
0
0
0
Other non-current liabilities
0
Total liabilities
4.97
3.42
7.81
22.7
16.2
22.8
31.8
24.3
27.3
17.2
Total debt
13.9
10.7
11.2
11.7
3.83
6.52
1
Paid-in capital
122
60
130
175
183
263
264
269
270
289
Retained earnings
-122
-39
-86.1
-137
-172
-238
-274
-291
-295
-301
Treasury stock
-1.13
-1.7
-1.83
-2.19
0
Other comprehensive income
0.02
Shareholders' equity
0.87
21.4
42.9
36.2
10.2
22.4
-10.7
-22.6
-24.3
-11.9
Total equity
0.87
21.4
42.9
36.2
10.2
22.4
-10.7
-22.6
-24.3
-11.9
Total liabilities and equity
5.85
24.8
50.7
58.9
26.5
45.1
21.1
1.71
2.98
5.27
Shares outstanding
0.73
0.69
0.89
1
1
2.17
2.17
3.14
3.53
0.44
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2025
FY2025
Net income
-5.8
-21.2
-47.2
-50.9
-34.6
-66.7
-36.1
-17.1
-3.14
-6
Depreciation and amortization
0.04
0.04
0.22
0.09
0.07
0.11
0.08
0.11
0.04
0
Stock-based compensation
0.08
0.1
13.4
11.3
8.67
9.17
3.02
1.97
0.54
0.24
Deferred income tax
-1.04
10.2
Change in receivables
0
-0.36
0.36
Change in payables
0.1
-0.58
-0.78
1.12
-1.39
-0.32
1.64
2.68
-0.35
-2.63
Cash from operations
-1.93
-15.9
-31.4
-39.4
-28.2
-35
-31.8
-14.3
-4.72
-6.33
Capital expenditures
-0
-0.24
-0.24
-0.04
-0.09
-0.07
Purchases of investments
-67.2
Sales and maturities of investments
33.8
33.8
Cash from investing
0.05
-0.11
-0.32
-33.5
33.8
2.06
-0.07
0.31
0.04
0
Debt issued
15
0.8
11.9
0
0
3.67
2.87
Stock issued
17
2.17
0.71
0.07
47.7
0
3.15
0
0
Dividends paid
0
0
0
Cash from financing
1.1
38
56.2
46.8
-3.44
50.8
8.81
-4.08
3.44
11
Net change in cash
-0.78
21.9
24.5
-26.1
2.19
17.8
-23.1
-18.1
-1.24
4.68
Free cash flow
-1.93
-16.2
-31.6
-39.4
-35.1
-31.9
Interest paid
0
0.99
0.83
0.73
1.37
0.99
0.14
0.03
Income taxes paid
0.04
0.01
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $15.03 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-145.4%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-100.0%
Revenue vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
77.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-37.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-27.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
228.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
78.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
65.3%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.31x
Current assets / current liabilities.
Quick ratio
0.28x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.28x
(Cash + short-term investments) / current liabilities.
Debt / assets
19.0%
Total debt / total assets.
Liabilities / assets
325.9%
Total liabilities / total assets.
Net debt
-$3.8M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.49
Net income per basic share, as reported (split-adjusted).
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.51
Cash from operations / diluted weighted shares.
Book value per share
-$27.35
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-9.9%
Net income / market cap (the inverse of P/E).
What was Eloxx Pharmaceuticals, Inc.'s revenue in fiscal 2025?
Eloxx Pharmaceuticals, Inc. reported revenue of $0.0 for fiscal 2025, 100% lower than the year before.
Was Eloxx Pharmaceuticals, Inc. profitable in fiscal 2025?
No. It reported a net loss of $6.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.